The chief medical officer of Stoke Therapeutics sold 14,311 shares of common stock for total proceeds of $457,000 across three days ending March 19, 2026. This is a routine insider disposal of modest size and is unlikely to be material to the company’s valuation, though it should be monitored for any further insider activity.
The chief medical officer of Stoke Therapeutics sold 14,311 shares of common stock for total proceeds of $457,000 across three days ending March 19, 2026. This is a routine insider disposal of modest size and is unlikely to be material to the company’s valuation, though it should be monitored for any further insider activity.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
